Equities analysts predict that Selecta Biosciences, Inc. (NASDAQ:SELB) will report earnings of ($0.88) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Selecta Biosciences’ earnings. Selecta Biosciences reported earnings per share of ($0.43) during the same quarter last year, which suggests a negative year over year growth rate of 104.7%. The firm is expected to announce its next earnings results on Thursday, November 9th.

On average, analysts expect that Selecta Biosciences will report full-year earnings of ($2.66) per share for the current fiscal year. For the next year, analysts anticipate that the firm will report earnings of ($3.23) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Selecta Biosciences.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. The business had revenue of $0.03 million during the quarter.

A number of analysts have commented on SELB shares. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Selecta Biosciences has a consensus rating of “Buy” and an average price target of $29.00.

TRADEMARK VIOLATION NOTICE: “-$0.88 EPS Expected for Selecta Biosciences, Inc. (SELB) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/13/0-88-eps-expected-for-selecta-biosciences-inc-selb-this-quarter.html.

In related news, CFO David Siewers sold 16,424 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $328,480.00. Following the completion of the sale, the chief financial officer now directly owns 2,194 shares of the company’s stock, valued at approximately $43,880. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amir Nashat sold 70,226 shares of the firm’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $18.91, for a total value of $1,327,973.66. The disclosure for this sale can be found here. Over the last three months, insiders sold 355,658 shares of company stock valued at $6,955,732. 41.90% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in SELB. Vivo Capital LLC acquired a new stake in Selecta Biosciences during the 2nd quarter valued at $22,227,000. Vanguard Group Inc. increased its holdings in Selecta Biosciences by 175.5% during the 2nd quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock valued at $4,322,000 after purchasing an additional 138,646 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Selecta Biosciences by 46.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock valued at $7,126,000 after purchasing an additional 114,477 shares in the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Selecta Biosciences by 306.5% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the company’s stock valued at $2,502,000 after purchasing an additional 95,000 shares in the last quarter. Finally, State Street Corp increased its holdings in Selecta Biosciences by 118.5% during the 2nd quarter. State Street Corp now owns 152,430 shares of the company’s stock valued at $3,027,000 after purchasing an additional 82,665 shares in the last quarter. 53.53% of the stock is owned by hedge funds and other institutional investors.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.